Taranabant

DB06624InvestigationalSmall molecule

Investigated for use/treatment in obesity.

Mechanism: Pharmacologically active on Cannabinoid receptor 1
Curator reviewed
Primary indication: Investigated for use/treatment in obesity.Curator reviewed
Formula / weight: C₂₇H₂₅ClF₃N₃O₂ · 515.96 g/mol (avg)
Code names: MK-0364 · MK-0634

Resolves to

Compound

Structure

InChIKeyQLYKJCMUNUWAGO-GAJHUEQPSA-NSMILESC[C@H](NC(=O)C(C)(C)OC1=CC=C(C=N1)C(F)(F)F)[C@@H](CC1=CC=C(Cl)C=C1)C1=CC=CC(=C1)C#N

Targets

What you can answer from here — as of June 15, 2026

1Protein targetEach mapped to UniProt, with action and pharmacological action

Listed above

781Drug interactionsStructured to mechanism, not free text

7Clinical trialsPhase, status and sponsor resolved per trial

3+ReferencesStructured and connected to the statements they support

Which drugs share a target with Taranabant, and which of those have an active Phase 3 trial?

Create a free account or log in to explore the full data card.